Sumatriptan/Naproxen helpful in treating teens' migraines

May 15, 2012
Sumatriptan/Naproxen helpful in treating teens' migraines

(HealthDay) -- Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents, according to a study published online May 14 in Pediatrics.

Frederick J. Derosier, D.O., from in Research Triangle Park, N.C., and colleagues conducted a involving teens (aged 12 to 17 years) who had two to eight migraines per month. The first moderate-to-severe attack was treated with placebo. Those with pain two hours after dosing were randomly assigned to receive a placebo (145 patients), 10/60 mg suma/nap (96), 30/180 mg suma/nap (97), or 85/500 mg suma/nap (152) for the second attack.

The researchers found that two-hour pain-free rates (adjusted for age and baseline severity) were significantly higher with suma/nap 10/60 mg (29 percent), 30/180 mg (27 percent), and 85/500 mg (24 percent) versus placebo (10 percent) for the second attack. There were no significant differences among the three doses. For sustained pain-free two to 24 hours, two-hour photophobia-free, and two-hour phonophobia-free, there were significant differences between 85/500 mg dosing and placebo. All active doses were well tolerated.

"All doses of suma/nap were well tolerated, providing similarly effective acute treatment of adolescent migraine pain and associated symptoms, as compared with placebo," the authors conclude.

Several authors disclosed to pharmaceutical companies, including GlaxoSmithKline, which manufactures sumatriptan and sodium and funded the study.

Explore further: Lower dose of corticosteroids just as effective as higher for shoulder pain

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Prophylaxis with apixaban feasible for cancer patients

March 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic cancer, is ...

ECO: New weight loss drug effective in advanced obesity

May 14, 2012

(HealthDay) -- A new combination treatment of controlled-release phentermine/topiramate (PHEN/TPM CR) leads to significantly greater weight loss than a placebo even in individuals with significant obesity-related comorbidities, ...

Recommended for you

Ebola virus mutations may help it evade drug treatment

September 11, 2015

Genetic mutations called "escape variants" in the deadly Ebola virus appear to block the ability of antibody-based treatments to ward off infection, according to a team of U.S. Army scientists and collaborators. Their findings, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.